At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 890 enrolled
Drug / intervention
Olopatadine 0.6% nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Study of Olopatadine Nasal Spray
In Brief
A Phase 3 clinical trial evaluating Olopatadine 0.6% nasal spray and Placebo Nasal Spray for Perennial Allergic Rhinitis. Completed, enrolled 890 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedDec 21, 2007
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.5 years ago
Interventions
Olopatadine 0.6% nasal spraydrug
2 sprays each nostril twice daily
Placebo Nasal Spraydrug
2 sprays each nostril twice daily